Jan 8 (Reuters) - Merck & Co Inc:
* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED RECURRENCE-FREE SURVIVAL COMPARED TO PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH STAGE 3 RESECTED HIGH-RISK MELANOMA (EORTC1325/KEYNOTE-054)
* MERCK & CO INC - PHASE 3 EORTC1325/KEYNOTE-054 TRIAL MET PRIMARY ENDPOINT OF RECURRENCE-FREE SURVIVAL
* MERCK -SAFETY PROFILE OF KEYTRUDA IN TRIAL WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES INVOLVING PATIENTS WITH ADVANCED MELANOMA
* MERCK & CO INC - IN ACCORDANCE WITH TRIAL PROTOCOL, STUDY WILL CONTINUE IN ORDER TO EVALUATE OTHER KEY ENDPOINTS, INCLUDING OVERALL SURVIVAL Source text for Eikon: Further company coverage:
 